30 C
Vientiane
Sunday, May 4, 2025
spot_img
Home Blog Page 29

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced completion of the first patient dosing for IBI3020, its first-in-class dual-payload CEACAM5 ADC, in Phase 1 clinical trial for the treatment of patients with advanced solid tumors. IBI3020 is the first dual-payload ADC developed from Innovent’s proprietary DuetTx® dual-payload ADC platform and the first dual-payload ADC globally known in the same class to complete the first-in-human dosing.

The study is an open-label, multi-regional Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IBI3020 in participants with advanced solid tumors, as well as determining the recommended Phase 2 dose (RP2D). The study has received IND approval in the U.S. recently and will be conducted in both China and the U.S.

As a global first-in-class ADC candidate, IBI3020 is generated from Innovent’s proprietary DuetTx® dual-payload ADC platform. The internationalization of the CEACAM5-dependent ADC occurs after IBI3020 selectively binds to CEACAM5-expressing tumor cells, followed by lysosomal degradation. This process releases two types of cytotoxic payloads, leading to cell killing of tumor cells.

In preclinical studies, IBI3020 has demonstrated robust antitumor activity across various tumor-bearing pharmacology models, with a notable bystander killing effect. Additionally, IBI3020 has shown favorable safety characteristics in preclinical models, with an overall manageable safety profile.

Professor Yu Jinming, Shandong Cancer Hospital, stated:” Carcinoembryonic antigen (CEA), also known as CEACAM5, is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein involved in cell adhesion, invasion, and metastasis of cancer cells. There is a significant clinical need for effective therapies in advanced colorectal cancer, non-squamous lung cancer, gastric cancer, pancreatic cancer, and others. CEACAM5 is overexpressed in these solid tumors but shows limited expression in healthy tissues, making it a potentially safe and promising therapeutic target. The dual payload of IBI3020 consists of two types of payloads that have been clinically validated. This dual-payload design has demonstrated enhanced tumor-killing effects in preclinical studies. We look forward to observing the clinical profiles and potential breakthrough of IBI3020 in terms of safety, tolerability, and efficacy in clinical trials.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “We are pleased to announce the successful dosing of the first patient dose with IBI3020. We will continue to advance the global development of IBI3020, aiming to offer better treatment options for patients with advanced solid tumors. Innovent possesses innovative ADC technology platforms with independent intellectual property rights. Multiple ADC molecules have clinically validated their differentiated competitiveness. IBI3020, Innovent’s first dual-payload ADC, has successfully entered clinical trials and is the first dual-payload ADC globally known in the same class to complete the first-in-human dosing, marking a breakthrough in Innovent’s ADC technology. We will continue our “IO+ADC” strategy, focusing on next-generation innovations with global potential to benefit cancer patients worldwide.”

About IBI3020

IBI3020 is a global first-in-class ADC candidate developed from Innovent’s proprietary DuetTx® dual-payload ADC platform. The CEACAM5 dependent ADC internalization occurs after IBI3020 selectively binds to the CEACAM5-expressing tumor cells, followed by the lysosomal degradation. This process releases two types of cytotoxic payloads, leading to tumor cell killing.

The multi-regional Phase 1 study of IBI3020, initiated in China, assesses the safety, tolerability, and preliminary efficacy of IBI3020 in patients with advanced solid tumors and aims to determine the recommended Phase 2 dose (RP2D). The study has also received IND approval in the U.S. recently and will be conducted in China and the U.S.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 16 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

( 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

137th Canton Fair Phase 2 Highlights Quality Home Life Through Innovation and Green Thinking

GUANGZHOU, China, April 30, 2025 /PRNewswire/ — Phase 2 of the 137th China Import and Export Fair (Canton Fair), taking place from April 23 to 27, spans an impressive 515,000 square meters of exhibition space. With 10,313 participating companies, 273 more than the previous session, this phase centers on quality home life.

In every household, the kitchen stands as a cornerstone of comfort and function. Yet even small daily challenges, like managing kitchen waste, can disrupt the rhythm of home life. That’s why even a simple product like a trash bin has become a beacon of innovation, with exhibitors at the Fair showcasing diverse solutions that cater to real consumer needs.

One standout comes from EKO Group Ltd., which exhibited a semi-round smart sensor bin that exemplifies the fusion of design and technology. This model features motion-activated, hands-free operation, a silent-closing lid, a removable inner bucket for easy cleaning, and a fingerprint-resistant stainless-steel body. Its sleek design reflects a growing consumer desire for functional products that elevate both hygiene and style in everyday spaces.

While some companies are enhancing waste management to improve the quality of home life, others are reimagining waste itself to elevate the essence of quality living. Intco Recycling Resources Co., Ltd., a high-tech manufacturer specializing in renewable resource recycling, is pioneering the transformation of recycled plastics into elegant, high-quality home décor. At their booth, buyers found photo frames, mirrors, table accessories, and other decorative items, all crafted entirely from recycled materials. These products not only reduce environmental impact but also prove that sustainability and sophisticated design can coexist.

The response from international buyers was enthusiastic. Du Mingze, Marketing Manager at Intco Recycling, noted that most inquiries on the first day came from European and Central Asian markets, reflecting a growing global appetite for eco-conscious living solutions.

From intelligent waste bins to recycled home items, Chinese companies at the Canton Fair are showing the world how innovation and environmental consciousness can go hand in hand. As the global demand for innovative and sustainable home products continues to grow, the Canton Fair demonstrates a powerful vision: a future where everyday living is elevated through design, enabled by technology, and sustained by green thinking.


 

Appian Embeds Agentic AI into Business Processes to Deliver Scalable, Governable Enterprise Value

Introducing new AI features and Data Fabric enhancements to deliver real-time insights and measurable impact.

SYDNEY, April 30, 2025 /PRNewswire/ — Appian (NASDAQ: APPN) today announced agentic AI platform enhancements to help organisations build, deploy, and scale intelligent process applications. As the Process Company, the Appian Platform provides AI-powered solutions to orchestrate and transform critical business processes. This release introduces the beta launch of Agent Studio and the general availability of AI Document Center. Additional enhancements include expanded data fabric support for document management and semantic search across data and documents.

Appian Embeds Agentic AI into Business Processes to Deliver Scalable, Governable Enterprise Value
Appian Embeds Agentic AI into Business Processes to Deliver Scalable, Governable Enterprise Value

Agentic AI makes business processes smarter and faster

Appian has embedded AI digital workers operating in process for years. Now with Agent Studio, Appian AI agents are more powerful and governable than ever. Agent Studio enables users to design and deploy AI agents with greater autonomy and contextual awareness. These AI agents can reason through complex, multi-step tasks. They can also interact with multiple systems to update records, send emails, and respond dynamically to new inputs. Agent Studio allows developers to create intelligent agents that not only execute actions but also make informed decisions based on real-time data and business logic.

Users can quickly and easily create agents for document processing with AI Document Center — an all-in-one application for enterprise-grade IDP. AI Document Center is designed to handle complex document formats with high extraction accuracy and scalability for enterprise workloads. Appian customer, Century Fire Protection, used AI Document Center to automate their accounts payable with AI, reducing invoice operating time by 36%.

“Adding Appian AI into Century’s AP management workflow has resulted in a more modern, controlled and efficient process, leading to significant benefits,” said Alex Polyakman, CFO of Century Fire Protection.

Smart search leverages AI-driven semantic search to enhance record retrieval. Smart search allows you to search across your entire data fabric, including text fields or documents attached to a record—all at enterprise scale. Smart search goes beyond keyword matching by interpreting intent, uncovering connections, detecting patterns, and surfacing related records.

In addition to high-availability, generative AI Agents can now be used in autoscale processes, helping enterprises stay responsive and efficient even when demand increases. Autoscale is an Appian Cloud capability that dynamically adjusts process execution capacity based on demand. Specifically designed for high-volume, high-throughput automation, process autoscale delivers 10-100x the power without over-provisioning resources. Now, organisations can power their high-volume, high-value generative AI use cases with enterprise-grade AI.

Other platform enhancements to data fabric and total experience include:

  • Data fabric now includes native support for documents. Organisations can manage, relate, and secure documents using record types, eliminating the need for folder-based organisation and allowing developers to create more document-centric applications.
  • Incremental syncs support dynamic data environments. Data fabric now supports external data sync as frequently as every 15 minutes and up to 20 million rows per record to ensure current, responsive applications.
  • Form headers and wizards accelerate beautiful form design. Appian UIs now automatically incorporate common form header, wizard functionality, and recommend modern UX patterns. Forms generated from data fabric will see the most improvements.

“AI works best in a process. Appian’s process orchestration and data fabric provide the foundation needed to get real value out of AI while maintaining data security,” said Michael Beckley, CTO and Founder, Appian.

Appian is the Process Company, focused on improving processes that define a business—from how it operates to how it serves customers and delivers value. By integrating AI into processes, Appian gives AI purpose, governance, and accountability—all essential to delivering its value. Learn how AI can be part of your processes.

About Appian

Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world’s largest companies across industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

Photo – https://laotiantimes.com/wp-content/uploads/2025/04/appian_agentic_ai.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/04/appian_400px_blank_logo.jpg

Goodme, China high-quality and cost-effective fresh fruit tea earns popularity among Japanese tourists

TOKYO, JAPAN – Media OutReach Newswire – 30 April 2025 – With the visa-free transit policy for Japanese tourists implemented by China at the end of 2024, as well as its high-quality yet low-cost consumption and geographical advantages, an increasing number of Japanese tourists have been attracted to China and it is integral part of their pleasure-seeking experience to eat, drink and be merry. Among them, healthy and delicious Chinese fresh fruit tea has become a must-have on the journey. As a Chinese freshly made tea beverage brand, Goodme has naturally become a classic try for Japanese tourists with its product strengths in quality-price performance and brand influence.

On April 18, the A+ Cheese Grape Fruit Tea, one of the classics offered by Goodme as a Chinese freshly made tea beverage brand made its return, with the cumulative sales exceeding 230 million cups. The tea beverage made of seasonal grapes costs only RMB 20 yuan, equivalent to about 388 yen, in China, while a cup of Summer Black grapevine fruit tea costs 1,150-1,250 yen in Japan, 3-4 times the price in China. This Chinese freshly made tea beverage brand has earned great popularity among domestic and overseas consumers with its excellent product strengths and market reputation.

It is the great value for the price and rich product variety that make the Chinese fresh fruit tea a classic delicacy. In the offline franchise stores of Goodme, a cup of grape-made fruit tea, pineapple-made fruit tea, or apple-made fruit tea costs 389 yen, while in Japan it costs 518-1250 yen, 2-3 times more than the price of similar products in China, let alone the lack of the apple-made fruit tea in Japan.

As China continues to relax its visa-free policies, the enthusiasm of Japanese tourists visiting China is soaring. It has become a phenomenal experience with the sense of ritual among them to try the Chinese fresh fruit tea. Goodme is not only popular in China but also well loved by more and more Japanese tourists nowadays. “Day day good me day day good” has gradually become a prevailing fashion trend among the younger generation at home and abroad.

As of now, Goodme has opened more than 10,000 stores as the only freshly made beverage brand in the world with more than 10,000 stores to adopt fresh ingredients. As it was listed in Hong Kong this February, Goodme has formulated a strategic plan to expand overseas markets.

Hashtag: #Goodme

The issuer is solely responsible for the content of this announcement.

About Goodme

Goodme is one of China’s freshly made tea beverage brands, with the highest annual sales of nearly 1.2 billion cups in 2023. It is known for high-quality ingredients with a short shelf life for freshly made beverage delivered by its cold chain logistics, featuring the freshness in every cup that “you can have every day and never get tired of”. It was listed in Hong Kong, China in February 2025 (stock code: 01364).

AIA Singapore celebrates SG60 with a year of initiatives to empower holistic well-being across the nation

Aligned to the theme of “Building Our Singapore Together”, the efforts aim to make a meaningful impact on Singaporeans of all generations


SINGAPORE – Media OutReach Newswire – 30 April 2025 – AIA Singapore today announced a year-long line-up of initiatives designed to connect with Singaporeans across all ages, empowering individuals to enhance their holistic wellness. Aligned with nationwide celebrations, these initiatives also emphasise giving back to the community, reinforcing AIA Singapore’s commitment to continue making a meaningful impact in Singapore and for its people.

These initiatives include:

  • Launching a customised “Live Better with AIA” Monopoly game set to empower individuals and families to embrace a holistic approach to life, focusing on physical, financial, and mental wellbeing.
  • Rolling out a family-centric campaign to encourage Singaporeans to strengthen and secure their family’s financial future.
  • Partnering with Rainforest Wild ASIA at the Mandai Wildlife Reserve to inspire a love for nature and wildlife amongst Singaporeans by encouraging meaningful connections that improve wellbeing.
  • Series of events specifically catered to affluent and High-Net-Worth (HNW) clients from the AIA Altitude programme, providing them with bespoke experiences that reflects our ‘Wealthbeing by AIA’ proposition.
  • Strengthening community bonds with Corporate Social Responsibility (CSR) activities focused on giving back to less-privileged members of society communities and making a positive social impact.

“AIA Singapore has proudly championed the health and well-being of Singaporeans across generations. As needs evolve, we remain committed to introducing innovative initiatives that promote holistic well-being and redefine what it means to live a healthy and active lifestyle. As Singapore marks its 60th birthday, we reaffirm our dedication to helping Singaporeans live Healthier, Longer, Better Lives,” said Irma Hadikusuma, Chief Marketing and Healthcare Officer of AIA Singapore.

Live Better with AIA x Monopoly
The “Live Better with AIA” Monopoly game set is Singapore’s first-ever insurer-customised edition of the iconic game. Designed to reflect the nation’s unique culture and experiences, it takes players through key life milestones and decisions, highlighting challenges and opportunities in health, wellness, financial planning, and social responsibility.

Some stand-out features of the “Live Better with AIA” Monopoly game set include:

  • Street tiles representing a Singaporean’s continuous journey of self-growth: Each tile represents distinct lifestyle enhancements, from essential needs to ultimate luxury. By integrating local cultural elements and unique Singaporean experiences, the tiles are designed to reflect the players’ diverse aspirations.
  • Traditional houses and hotels replaced with Upgrades and Transformations: Upgrade represents a significant milestone in enhancing one’s lifestyle, such as advanced workshops, personalised wellness plans, or high-end home features. Transformations signify even higher levels of achievement, like attaining expert certifications, investing in luxury property, or accessing exclusive experiences.
  • ‘Chance’ cards with a local flavour: Chance cards incorporate Singaporean slang while retaining their original outcomes. Players are encouraged to get up and move to earn their cash, promoting an active lifestyle.
  • ‘Community chest’ cards with relatable life moments and community engagement: Players can experience a range of real-life scenarios, such as earning bonuses, receiving angbao money at Chinese New Year, and celebrating family milestones like winning an award.

Irma said, “The Live Better with AIA Monopoly goes beyond financial planning. It’s a platform for families to bond over, learn together, and make informed decisions that enhance their holistic wellbeing. It’s not just about winning – it’s about building a life filled with purpose, personal growth, and meaningful connections.”

The “Live Better with AIA” Monopoly game set is exclusively available through AIA insurance representatives. More details can be found here: www.aia.com.sg/monopoly

AIA Better Together Promotion
To celebrate SG60 and the National Family Festival in June, AIA Singapore is launching a special campaign to help families safeguard their financial future. From 6 May to 31 July 2025, AIA Singapore is offering up to 20% off eligible plans plus a free family adventure pass to Mandai Wildlife Reserve (worth S$200).

This initiative aligns with the national focus on families, empowering Singaporeans—especially young families—to build a strong financial foundation for the future. It also reflects AIA Singapore’s commitment to supporting and strengthening families, recognising their vital role in shaping a resilient society. More details on tthe promotion can be found here from 6 May: www.aia.com.sg.

AIA Singapore’s tapir adoption and AIA Vitality bounce sponsorship at Rainforest Wild ASIA
In February this year, AIA Singapore celebrated the opening of Rainforest Wild ASIA at Mandai Wildlife Reserve, reinforcing its commitment to community engagement, wildlife conservation, and healthier lifestyles. As AIA Singapore continues to support initiatives that promote well-being and sustainability, this collaboration aligns with the AIA One Billion initiative, which aims to empower one billion people to live Healthier, Longer, Better Lives by 2030. For more details, please refer to the press release.

Elevating the ‘Wealthbeing by AIA’ Proposition for high-net-worth clients (HNW)
As part of AIA Singapore’s continued efforts to serve affluent and HNW clients in Singapore and across the region, a curated series of events, momentos and experiences catering specifically to AIA Altitude members will be held throughout the year. Members of the by-invite-only programme will be provided access to unique and bespoke opportunities that reflect the ‘Wealthbeing by AIA‘ proposition, our belief that true wealth transcends mere financial wellness and encompasses holistic wellness.

Additionally, AIA Altitude Pinnacle members celebrating their 60th birthday in 2025 will be gifted an exclusively designed Silk Scarf designed by local designer and founder of Singapore lifestyle brand Onlewo, Mike Tay[1]. The design on the scarf captures the dynamic blend of Singapore’s heritage and progressive nature. The exquisite design mirrors AIA Singapore’s commitment to evolve alongside customers as a trusted partner in health and wealth, a similar reflection Singapore’s transformation in the past six decades into a metropolitan city.

AIA Altitude will also be partnering with the Michelin Guide to present Gastronomic Heritage, a booklet featuring prominent four family-owned restaurants and chefs from Singapore, each with a rich legacy spanning multiple generation. Pulling parallels between these eateries and one’s wealth planning journey, Gastronomic Heritage will spotlight key values about legacy building and inheritance, spurring AIA Altitude members to curate conversations about growing and protecting their wealth holistically. They will also be treated to an experiential, specially curated dish or experience at these featured restaurants.

Other exclusive events for AIA Altitude members lined up for the year include wine and sake pairing sessions with featured brands from Gastronomic Heritage, exclusive SG60 National Day celebration at the AIA Wealth Centre overseeing the view of Padang, a trip to local Gin distillery Brass Lion, paired with a hands-on experience to craft an exclusive bottle of Gin infused with familiar local flavours, and more.

Beyond leisure and enjoyment, these events will also incorporate insightful business topics, ranging from investment strategies and legacy planning to wealth enhancement, empowering AIA Altitude members to achieve holistic success in both their personal and professional lives.

AIA strengthens community bonds through increased focus on CSR Initiatives
AIA Singapore is dedicating the year to giving back to the community through a series of CSR initiatives, with AIA staff and insurance representatives participating in volunteer programmes to support those in need. Its adopted charities will also be invited to share about their mission and needs at various AIA office locations, encouraging employees and AIA insurance representatives to contribute meaningfully. This year, we will also recognise and celebrate the efforts of “AIA Connecting Lives” volunteers who dedicate their time to serving the community.

Additionally, as part of AIA Singapore’s sponsorship of Mandai Rainforest Wild Asia, special edition tapir plushies will be available for sale with all proceeds going to the AIA Better Lives Fund.

“SG60 is not just a time for celebration but also a moment of reflection on our shared values and goals as Singaporeans. This year, as we embrace ‘Building Our Singapore Together,’ we recognise that each of us has a role to play in supporting one another and shaping a stronger, more resilient nation,” said Irma.


[1] Mike Tay was also featured among the top 50 Most Influential Singapore Designer in Singapore Tatler Homes, 2016. More information available at: https://saineofficial.wordpress.com/2020/12/23/founder-of-onlewo-mike-tay-on-telling-the-singapore-story-through-fabrics/#:~:text=Mike%20Tay%20is%20the%20founder,in%20Singapore%20Tatler%20Homes%2C%202016.

* AIA Better Together Promotion 2025 Terms & Conditions apply

Hashtag: #AIASingapore

The issuer is solely responsible for the content of this announcement.

About AIA

AIA Group Limited and its subsidiaries (collectively “AIA” or the “Group”) comprise the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets – wholly-owned branches and subsidiaries in Mainland China, Hong Kong SAR[1], Thailand, Singapore, Malaysia, Australia, Cambodia, Indonesia, Myanmar, New Zealand, the Philippines, South Korea, Sri Lanka, Taiwan (China), Vietnam, Brunei and Macau SAR[2], and a 49 per cent joint venture in India. In addition, AIA has a 24.99 per cent shareholding in China Post Life Insurance Co., Ltd.

The business that is now AIA was first established in Shanghai more than a century ago in 1919. It is a market leader in Asia (ex-Japan) based on life insurance premiums and holds leading positions across the majority of its markets. It had total assets of US$305 billion as of 31 December 2024.

AIA meets the long-term savings and protection needs of individuals by offering a range of products and services including life insurance, accident and health insurance and savings plans. The Group also provides employee benefits, credit life and pension services to corporate clients. Through an extensive network of agents, partners and employees across Asia, AIA serves the holders of more than 43 million individual policies and 16 million participating members of group insurance schemes.

AIA Group Limited is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock codes “1299” for HKD counter and “81299” for RMB counter with American Depositary Receipts (Level 1) traded on the over-the-counter market under the ticker symbol “AAGIY”.


[1] Hong Kong SAR refers to the Hong Kong Special Administrative Region.
[2] Macau SAR refers to the Macau Special Administrative Region.

JustMarkets Launches Improved IB Program Focused on Transparency and Unlimited Growth


JAKARTA, INDONESIA – Media OutReach Newswire – 30 April 2025 – Global broker JustMarkets announces the official launch of its updated Introducing Broker (IB) program, which is designed to provide partners with higher returns, transparent terms, and unlimited growth potential, adapted to the current macroeconomic environment.

JustMarkets Launches Improved IB Program
JustMarkets Launches Improved IB Program

JustMarkets continues to focus on partner success by introducing an updated IB program adapted to the demands of current market conditions. The expanded program eliminates outdated conditions such as the Minimum Trading Point (MTP) requirement. It also introduces a flexible percentage commission structure, offering partners up to 40% of the spread on all trading instruments, including gold, oil, forex, and digital assets.

JustMarkets believes that traders and partners should be at the center of all the innovations and services we introduce. The improved IB program is a powerful tool for partners to take advantage of new opportunities, grow their businesses, and thrive in highly volatile financial markets. The goal is to provide the industry’s most transparent and rewarding partnership environment.” — Yasser Mansour, Senior Key Account Manager, JustMarkets.

Key features of the Improved IB program

  • Highest commissions in the market: Partners can earn up to 40% of the spread on Standard and Standard Cent accounts and up to 25% on Pro accounts. JustMarkets provides full profit on every trade without fixed lot payouts that exclude certain trades.
  • No MTP requirements: JustMarkets count towards commissions of all trades, including scalping and short-term strategies. Partners no longer face filtered payouts or partial volumes.
  • Increased Revenue During Volatility: Higher spreads during volatile market conditions directly translate into higher partners rewards, as the percentage model dynamically adjusts to market movements.
  • Faster Growth and Loyalty Rewards: Without MTP rules, partners can increase loyalty levels faster, benefiting from a more generous reward structure.
  • JustMarkets secures current partner level for two months after launch, ensuring a smooth transition.
  • Full Transparency: JustMarkets provides partners with real-time access to view client spreads directly in the trading terminal. This provides full insight into how commissions are calculated, building trust and control over earnings.

All strategies supported – scalping, intraday, or long-term trading, are rewarded. Unlike flat lot commission programs where some trades go unpaid, JustMarkets partners earn more by capturing 100% of client trading volume.

The move from flat lot commission to a percentage-based system reflects JustMarkets commitment to adapting to market trends and offering its partners a fair, scalable, and profitable environment. JustMarkets transparent percentage model pays for every trade, ensuring that partners get the most out of their clients trading activity.

New Opportunities in New Financial Markets Era

This essential update comes from JustMarkets mission to create a convenient and transparent trading environment that allows traders and partners to reach their full potential regardless of the unpredictable macroeconomic situation. Through extensive market analysis, the company has aligned its partner offering with current industry trends and partner expectations.

This is about real, consistent, and fair rewards for our valued partners. We offer our partners a program that truly reflects the value and transparency they bring. Every deal matters, every client matters, and every partner matters for JustMarkets.
– JustMarkets Representative

Visit Partner Area to learn detailed commission structures, prepare for the next chapter of partnership with JustMarkets, and take it to the next level. JustMarkets 24/7 support team is ready to help with any questions and ensure a smooth transition into this new era of partnership.

Hashtag: #JustMarkets

The issuer is solely responsible for the content of this announcement.

JustMarkets

JustMarkets is a globally recognized multi-asset broker providing reliable and transparent trading services since 2012. The company has earned over 60 industry awards, highlighting its excellence in the financial sector. JustMarkets offers a diverse array of trading instruments, including forex, stocks, commodities, indices, metals, energies, and cryptocurrencies, serving clients in over 160 countries.

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong

SHANGHAI, April 30, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the Government of the Hong Kong Special Administrative Region, China, has officially approved the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Following approvals in the Macau and Singapore, Hong Kong has become the third region within Everest Medicines’ licensed territory to approve VELSIPITY®. NMPA of China has also officially accepted the NDA for VELSIPITY® for the treatment of patients with moderately to severely active UC in December 2024.

VELSIPITY® is an effective and convenient, once-daily, oral treatment for adult patients with moderately to severely active UC that has already been approved in the U.S., E.U., and other countries by Everest’s licensing partner, Pfizer. The approval of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12). Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod. Etrasimod has been included in the AGA Living Clinical Practice Guideline on the pharmacological management of moderate-to-severe UC as one of the higher-efficacy medications suggested for first line use in advanced therapy-naïve patients.

“The approval of VELSIPITY® in Hong Kong marks an important milestone in bringing this innovative therapy to UC patients,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “In 2022, there were approximately 600,000 patients with UC in China, and the number is estimated to reach 1 million by 2030, reflecting the significant unmet need for advanced treatment options. VELSIPITY® has already been introduced to hospitals in the Greater Bay Area through the ‘Hong Kong and Macau Medicine and Equipment Connect’ policy. With the NDA for VELSIPITY® officially accepted by the NMPA, we look forward to expanding patient access to this therapy.”

Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial said: “As a next-generation selective S1P receptor modulator, once-daily oral etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization and histological remission. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. We look forward to its approval in more regions to benefit more patients.”

As a core product of Everest Medicines, etrasimod is an innovative and advanced therapy that provides the chance for rapid onset of action, clinical remission and mucosal healing through an oral, once-daily regimen. Etrasimod has been commercially launched in Singapore and Macau in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched the construction project at its Jiashan factory to support the local production for VELSIPITY®.

About VELSIPITY® (etrasimod)

VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and the Macau SAR, China for VELSIPITY® in ulcerative colitis, as well as additional countries.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

KT Corp. Files 2024 Annual Report on Form 20-F

SEOUL, South Korea, April 30, 2025 /PRNewswire/ — KT Corporation (NYSE: KT), South Korea’s leading integrated telecommunications and platform service provider, announced that it has filed its Form 20-F Annual Report on April 29th, 2025 for the year ended December 31, 2024 with the Securities and Exchange Commission of the United States. The report can be accessed on KT’s English website at https://corp.kt.com/eng in the Investors section under Business Report as well as the SEC’s Edgar database at www.sec.gov.

About KT Corporation (KRX: 030200; NYSE:KT)

KT Corporation is the leading integrated telecommunications and platform service provider based in South Korea. Principal services include mobile, Broadband, IPTV, B2B communications, and fixed-line telephony. The Company has industry-leading market presence in Broadband, media services, and fixed-line telephony by maintaining No.1 market share positions. Also, the Company is the No.1 player in B2B communications and offers a wide range of other information technology and network services including data centers and cloud services. Additionally, the Company possesses a well-balanced portfolio of diverse subsidiaries focusing on media/content, financial services, real estate operations, and commerce industries.

Forward-Looking Statements

This communication contains “forward-looking statements” that are based on our current expectations, assumptions, estimates and projections about us and the industries in which we operate. The forward-looking statements are subject to various risks and uncertainties. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “project,” “should,” and similar expressions. Those statements include, among other things, the discussions of our business strategy and expectations concerning our market position, future operations, margins, profitability, liquidity and capital resources. We caution you that reliance on any forward-looking statement involves risks and uncertainties, and that although we believe that the assumptions on which our forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and, as a result, the forward-looking statements based on those assumptions could be incorrect. The uncertainties in this regard include, but are not limited to, those identified in the risk factors discussed above. In light of these and other uncertainties, you should not conclude that we will necessarily achieve any plans and objectives or projected financial results referred to in any of the forward-looking statements. We do not undertake to release the results of any revisions of these forward-looking statements to reflect future events or circumstances.

IR department:
+82-70-4193-4036
ktir@kt.com